Curriculum Vitae David Zimrin, M.D.
Date: October 4, 2007 Personal Information University of Maryland Medical Center Division of Cardiology 22 S. Greene Street, Room S3B08 Baltimore, MD 21201 Office – 4103283244 Education 1972 – 1976 1976 – 1980
BA MD
University of Pennsylvania Mount Sinai School of Medicine
Post Graduate Education and Training 1980 – 1981 Internship Hospital of the University of Pennsylvania 1981 – 1983 Residency Hospital of the University of Pennsylvania 1983 – 1985 Fellow Cardiology, Hospital of the University of Pennsylvania 1985 – 1986 Fellow Interventional Cardiology, Hospital of the University of Pennsylvania Certifications 1983 Diplomate, American Board of Internal Medicine 1985 Diplomate, American Board of Internal Medicine, Cardiovascular Disease 2000 Diplomate, American Board of Internal Medicine, Interventional Cardiology Medical Licensures Maryland D33745 Pennsylvania MD026345E (inactive) Membership in Professional Societies: 1986 present Fellow American College of Cardiology 2005 present Fellow Society for Cardiovascular Angiography and Interventions Employment History Academic 1987 – 1997 Assistant in Medicine, Johns Hopkins School of Medicine 1987 – 2005 Clinical Instructor in Medicine, University of Maryland School of Medicine 2005 – present Assistant Professor of Medicine, University of Maryland School of Medicine
David Zimrin, M.D. Assistant Professor of Medicine Other 1986 – 2004
2
Midatlanic Cardiovascular Associates, P.A. (formerly Cardiovascular Associates of Baltimore)
2
David Zimrin, M.D. Assistant Professor of Medicine
3
Major Clinical Tasks 1988 – 1991 Director, Coronary Care Unit, Homewood Hospital Center 1989 – 1992
Chief, Division of Cardiology, Wyman Park Medical Associates, Johns Hopkins Medical Services
1992 – 2004
Director, Interventional Cardiology, Sinai Hospital
2005 – present Director, Cardiac Catheterization Laboratory, University of Maryland Medical Center 2006 – present Director, Interventional Cardiology Fellowship Program, University of Maryland School of Medicine Honors and Awards 19721976 Benjamin Franklin Scholar, University of Pennsylvania 1975 Phi Beta Kappa, University of Pennsylvania 1976 Magna Cum Laude, University of Pennsylvania 1979 Alpha Omega Alpha, Mount Sinai School of Medicine 1979 Mosby Book Award (Medicine), Mount Sinai School of Medicine Administrative Service Institutional 2005 – present Cardiovascular Executive Committee Member, University of Maryland 2005 – present Quality Physician for Cardiology, University of Maryland 2005 – present Member, Department of Medicine Quality Improvement Committee 2006 – present School of Medicine Council, Alternate Member, University of Maryland National 2006 – present Manuscript Reviewer, Mayo Clinic Proceedings 2006 – 2007 Member, Training Program Standards Committee, Society of Cardiovascular Angiography and Interventions Teaching Service 2005 – present 2005 – present 2005 – present
Attending Physician Cardiology Consult Service (1 fellow, 2 residents, 2 students) 4 weeks /year Attending Physician Cardiac Catheterization Lab (5 fellows) 46 weeks/year Attending Physician Outpatient Cardiology Clinic (1 fellow) two 4 hour sessions/week 46 weeks/year
3
David Zimrin, M.D. Assistant Professor of Medicine
4
2006 present
Initiated and Coordinating quarterly Cardiology Morbidity and Mortality Conference 2005 – present Coordinate/Teach weekly Cardiac Catheterization Conference 2007 Lecturer first year student School of Medicine Functional Systems (physiology) cardiology clinical correlation 2007 Instructor second year student School of Medicine cardiology clinical correlation (small groups) 2007 Instructor second year students School of Medicine cardiac physical diagnosis (small groups) Grant Support Extramural Peer Reviewed Grant Funding 1984 American Heart Association Fellowship Grant. David Zimrin (Principal Investigator): Effect of Dobutamine on Mechanical Determinants of MV02 in Dilated Cardiomyopathy. $5,000 2007
Maryland Industrial Partnerships (MIPS) Grant. David Zimrin (Principal Investigator): Innovations in Platelet Function Assessment. $160,000
Industry Supported Trials 1995
Otsuka America Pharmaceuticals. David Zimrin (Principal Investigator): A Randomized DoubleBlind Placebo Controlled Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure (VEST Trial)
1996 SCIMED. David Zimrin (Principal Investigator): Perfusion Balloon Catheter Clinical Trial 1996
David Zimrin (Principal Investigator): Safety and Efficancy of Zemilogiban Hydrochloride. (SC54684A) Administration to Patients with Stable or Unstable Angina or Hospitalized for a Recent Myocardial Infarction and Have Completed Coronary Revascularization
1996HoffmanLaRoche. David Zimrin (Principal Investigator): A Comparison of the Effects of Mibefradil Versus Placebo for Three Weeks in Patients with Chronic Stable Angina Pectoris 1997
SCIMED. David Zimrin (Principal Investigator): Stent Comparative Restenosis Trial (SCORES trial)
1999
David Zimrin (Principal Investigator): DoubleBlind, Ranomized, Multicenter Trial of SingleBolus Lanteplase vs Acceslerated Alteplase for the Treatment of Subject with Acute Myocardial Infarction (inTIME II)
2000
David Zimrin (Principal Investigator): A Phase III, Multicenter, International, Randomized, DoubleBlind, AspirinControlled Trial to Evaluate the Efficacy and Safety of Sibrafiban (Ro 483657), an Oral Platelet Glycoprotein Iib/IIIa Antagonist, as Therapy for the Prevention after an Acute Coronary Syndrome (SYMPHONY) 4
David Zimrin, M.D. Assistant Professor of Medicine 2000
2001
5
David Zimrin (Principal Investigator): A Phase II, Randomized, DoubleBlind, Multicenter Acetylasalicycli Acid (ASA) Controlled, MultiDose Study of DMP574 in Patients with Coronary Artery Disease (ROXIFIBAN) David Zimrin (Principal Investigator): A Randomized, DoubleBind Placebo Controlled DoseRanging Study to Determine the Safety and Efficacy of AMP579 in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty (AMP579)
2005David Zimrin (CoInvestigator): Coronary Angioplasty Recurrent Event Study (CARES): Behavioral and Immunological Factors in Coronary Disease. 2005
David Zimrin (CoInvestigator): A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the StarFlex Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale.
2005
David Zimrin (CoInvestigator): PERISCOPEA Double Blind Randomized ComparatorControlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCL Versus Glimepiride on the Rate of Progression of Coronary Atherosclerosis Disease as Measured by Intravascular Ultrasound.
2005
David Zimrin (CoInvestigator): A Comparison of CS747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Protocol Number H7TMCTAAL.
2005
David Zimrin (CoInvestigator): A Multicenter, Randomized, DoubleBlind, Parallel Group, Phase IV Study to Compare the Renal Effects of a NonIonic IsoOsmolar Contrast Medium (IOCM), Visipaque, with a NonIonic Low Osmolar Contrast Medium (LOCM) in Subjects with Impaired Renal Function and Diabetes Mellitus Undergoing Coronary Angiography.
2005 David Zimrin (CoInvestigator): Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) 2007
David Zimrin (Co Investigator) Study of Platelet Inhibition and Patient Outcomes (PLATO) AZD6140 compared to clopidogrel in unstable coronary syndromes
Recent invited Lectures 2005 Thomas Jefferson Medical College, Philadelphia, PA. Kynett Foundation Annual Lecture. “Cardiac Catheterization: When and Why”
5
David Zimrin, M.D. Assistant Professor of Medicine 2006 2007
6
University of Maryland Department of Medicine Grand Rounds. “Cardiology Full Employment and the Vulnerable Plaque“ Thomas Jefferson Medical College, Philadelphia, PA. Kynett Foundation Annual Symposium. “Drug Eluting Stents: Insights into the Controversy”
Publications Journal Articles (Peer Reviewed) 1. Reichek N, Priest C, Zimrin D, Chandler T, St. John Sutton, M: Antianginal Effects of Nitroglycerin Patches. Am J Cardiology, 54:17, 1984. 2. Zimrin D, Reichek N, Bogin K, Aurigemma G, Douglas P, Berko B, Fung H. Antianginal Effects of Intravenous Nitroglycerin over 24Hours. Circulation, 77:13761384, 1988. 3. Zimrin D, Reyes P, Reicher B, Poston R. A Hybrid Alternative for high risk left main disease. Catheterization and Cardiovascular Interventions, 69:123127, 2007. 4. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, Grant MC, Kallam S, Burris NS, Connerney I, Zimrin D, Poston R. Simultaneous Hybrid Coronary Revascularization Reduces Postoperative Morbidity Compared to Conventional OffPump Coronary Artery Bypass. JTCVS (In Press) 5. Zimrin D, Reyes P, Miller KL, Fisher SD, Griffith BP, Gammie JS. Staged Balloon Aortic Valvuloplasty and Aortic Valve Bypass for “Inoperable” Aortic Stenosis. CHF (In Press) 6. Mehra M, Zimrin D, Benitez M, Reyes P, Gammie J. Surgery for Severe Mitral Regurgitation and Left Ventricular Failure: What Do We Really Know? Journal of Cardiac Failure (In Press) Abstracts 1. Reichek N, Priest C, Zimrin D, Chandler T, Raichlen J, St. John Sutton, M. Antianginal Effects of Nitroglycerin Patches Do Not Last 24Hours. Circulation, 68:III407, 1983. 2. Reichek N, Priest C, Zimrin D, Chandler T, Berger N, Douglas P, St. John Sutton, M. Antianginal Effects of Nitroglycerin Over 24Hours: Role of Method of Administration. Circulation, 70:II190, 1984. 3. Zimrin D, Reichek N, Bogen C, Cameron S, Douglas P, Fung H. Antianginal Efficacy of IV Nitroglycerin. Circulation, 72:III46, 1985. 4. Zimrin D, Reichek N, Bogen C, Cameron S, Douglas P, Fung H. IV Nitroglycerin: Infusion Rate, Plasma Concentration and Hemodynamic Effects. J of the Am Coll of Card, 7:181A, 1986.
6
David Zimrin, M.D. Assistant Professor of Medicine
7
5. Reichek N, Zimrin D, Bogin K, Douglas P, Berko B, Aurigemma G, Fung H. Tolerance to Antianginal Effects of Nitroglycerin. Clin Res, 34:338A, 1986. 6. Aurigemma G, Bogin K, Zimrin D, Douglas P, Berko B, Reichek N. Silent Ischemia During Submaximal Exercise and Anginal Threshold: Effects of Nitroglycerin. Clin Res, 35:259A, 1987. 7. Reicher B, Poston R S, Reyes P, Scaffidi R, Zimrin D. A Novel Strategy of Simultaneous Hybrid Minimally Invasive Coronary Artery Bypass Surgery/Drug Eluting Stents for Multivessel Coronary Artery Disease. Cardiovascular Revascularization Medicine, 7:2, 2006. 8. Reyes P, Poston R, Reicher B, Scaffidi R, Zimrin D. Simultaneous Hybrid MIDCAB/Stent for Multivessel CAD. Catheter Cardiovasc Interv, 67:793794, 2006. 9. Levine JC, Feseha H, Miller KL, Reyes PA, Reicher B, Joshi A, Poston RS, Zimrin D. Safety and Efficacy of Platelet Inhibition During Coronary Hybrid Revascularization Cardiovascular Research Medicine, 8:2, 2007. 10. Feseha H, Levine JC, Poston RS, Reicher B, Reyes P, Kon Z, Zimrin D. Platelet Function and Hybrid Coronary Revascularization. Catheter Cardiovasc Interv, 69:S7879, 2007. 11. Kon Z, Joshi A, Reicher B, Kallam S, Burris NS, Zimrin D, Poston R. Simultaneous Hybrid Coronary Revascularization Reduces Postoperative Morbidity Compared to Conventional Off Pump Coronary Artery Bypass. Oral presentation at AATS, 5/07, Washington , DC.
7